Pegylated versus non-pegylated interferon beta 1a in patients with relapsing-remitting multiple sclerosis: A cost-effectiveness analysis

Background: Pegylated (PEG) interferon beta 1a has been approved by the United States Food and Drug Administration (USFDA) as an alternative to interferon beta 1a for multiple sclerosis (MS). Due to its higher price, this study aimed to evaluate the cost-effectiveness of PEG-interferon beta 1-a comp...

Descripción completa

Detalles Bibliográficos
Autores principales: Hashemi-Meshkini, Amir, Zekri, Hedieh Sadat, Karimi-Yazdi, Hasan, Zaboli, Pardis, Sahraian, Mohammad Ali, Nikfar, Shekoufeh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Tehran University of Medical Sciences 2018
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6420694/
https://www.ncbi.nlm.nih.gov/pubmed/30886679

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6420694/
https://www.ncbi.nlm.nih.gov/pubmed/30886679

Ejemplares similares